Repository logo
 

Two novel, putative mechanisms of action for citalopram-induced platelet inhibition.

Simple item page
cam.issuedOnline2018-11-12
dc.contributor.authorRoweth, Harvey G
dc.contributor.authorCook, Aaron A
dc.contributor.authorMoroi, Masaaki
dc.contributor.authorBonna, Arkadiusz M
dc.contributor.authorJung, Stephanie M
dc.contributor.authorBergmeier, Wolfgang
dc.contributor.authorSage, Stewart O
dc.contributor.authorJarvis, Gavin E
dc.contributor.orcidBonna, Arkadiusz M [0000-0002-3957-7849]
dc.contributor.orcidJarvis, Gavin E [0000-0003-4362-1133]
dc.date.accessioned2018-12-07T00:30:38Z
dc.date.available2018-12-07T00:30:38Z
dc.date.issued2018-11-12
dc.description.abstractCitalopram, a selective serotonin reuptake inhibitor (SSRI), inhibits platelet function in vitro. We have previously shown that this action is independent of citalopram's ability to block serotonin uptake by the serotonin transporter and must therefore be mediated via distinct pharmacological mechanisms. We now report evidence for two novel and putative mechanisms of citalopram-induced platelet inhibition. Firstly, in platelets, citalopram blocked U46619-induced Rap1 activation and subsequent platelet aggregation, but failed to inhibit U46619-induced increases in cytosolic Ca2+. Similarly, in neutrophils, citalopram inhibited Rap1 activation and downstream functions but failed to block PAF-induced Ca2+ mobilisation. In a cell-free system, citalopram also reduced CalDAG-GEFI-mediated nucleotide exchange on Rap1B. Secondly, the binding of anti-GPVI antibodies to resting platelets was inhibited by citalopram. Furthermore, citalopram-induced inhibition of GPVI-mediated platelet aggregation was instantaneous, reversible and displayed competitive characteristics, suggesting that these effects were not caused by a reduction in GPVI surface expression, but by simple competitive binding. In conclusion, we propose two novel, putative and distinct inhibitory mechanisms of action for citalopram: (1) inhibition of CalDAG-GEFI/Rap1 signalling, and (2) competitive antagonism of GPVI in platelets. These findings may aid in the development of novel inhibitors of CalDAG-GEFI/Rap1-dependent nucleotide exchange and novel GPVI antagonists.
dc.description.sponsorshipBritish Heart Foundation
dc.format.mediumElectronic
dc.identifier.doi10.17863/CAM.33694
dc.identifier.eissn2045-2322
dc.identifier.issn2045-2322
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286381
dc.languageeng
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.publisher.urlhttp://dx.doi.org/10.1038/s41598-018-34389-5
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
dc.subjectCalcium
dc.subjectCitalopram
dc.subjectCytosol
dc.subjectHumans
dc.subjectL-Lactate Dehydrogenase
dc.subjectModels, Biological
dc.subjectNeutrophils
dc.subjectPlatelet Aggregation
dc.subjectPlatelet Aggregation Inhibitors
dc.subjectPlatelet Membrane Glycoproteins
dc.titleTwo novel, putative mechanisms of action for citalopram-induced platelet inhibition.
dc.typeArticle
dcterms.dateAccepted2018-10-12
prism.issueIdentifier1
prism.publicationDate2018
prism.publicationNameSci Rep
prism.startingPage16677
prism.volume8
pubs.funder-project-idBritish Heart Foundation (None)
pubs.funder-project-idBritish Heart Foundation (None)
pubs.funder-project-idBritish Heart Foundation (FS/13/63/30437)
pubs.funder-project-idBritish Heart Foundation (None)
rioxxterms.licenseref.startdate2018-11-12
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41598-018-34389-5

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41598-018-34389-5.pdf
Size:
3.11 MB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
https://creativecommons.org/licenses/by/4.0/
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreementv2.1.pdf
Size:
150.9 KB
Format:
Adobe Portable Document Format
Download

Collections

Cambridge University Research Outputs